New Mouse Model May Improve Virus-Driven Liver Cancer Diagnosis and Treatment

Researchers at The Rockefeller University have developed a new mouse model that mirrors the progression of virus-driven liver cancer in humans, potentially facilitating the development of improved diagnostic tools and treatments.

The study, described in the Journal of Hepatology, addresses a long-standing challenge in medical research: the lack of an animal model that accurately replicates how chronic viral infections lead to liver cancer in people.

Liver cancer is recognized as one of the world’s deadliest forms of cancer. A significant majority of cases globally—more than three-quarters—are associated with chronic viral hepatitis.

Development of the Norway Rat Hepacivirus Model

To create the model, the team led by Charles M. Rice at the Laboratory of Virology and Infectious Disease infected ordinary laboratory mice with an engineered version of the Norway rat hepacivirus (NrHV).

The Norway rat hepacivirus is a close relative of the hepatitis C virus (HCV). By tracking the mice over a period of 18 months, the researchers documented a disease progression that closely follows the human experience of viral hepatitis.

The progression observed in the mice included the following stages:

• Initial chronic viral infection
• Liver inflammation
• Liver scarring
• Development of spontaneous liver cancer

This sequence of events mirrors the pathological process seen in humans with hepatitis C, providing a faithful recapitulation of how the disease unfolds from the initial infection to the final stage of malignancy.

Impact on Liver Cancer Research

Hepatocellular carcinoma (HCC) is the most common form of liver cancer and represents the third leading cause of cancer death worldwide. More than 75% of individuals who develop HCC have a chronic infection with either the hepatitis C virus (HCV) or the hepatitis B virus (HBV).

Because previous animal models failed to accurately reflect this progression in immunologically healthy animals, researchers had limited ability to study the specific mechanisms by which these viruses trigger cancer.

This model fills a critical gap that has long existed in the field. For the first time, we have a system in which natural chronic viral infection drives liver cancer in an immunologically healthy animal, opening the door to studies and preclinical trials that simply weren’t possible before.

Charles M. Rice

The new model allows scientists to examine the interaction between viruses and the immune system to understand how they work together to trigger the onset of cancer.

Future Applications for Diagnosis and Treatment

The Rockefeller University team indicates that this model can now be used to study the specific pathways through which liver virus infections lead to cancer.

Beyond basic mechanistic research, the model is intended to serve as a platform for testing new treatments and conducting preclinical trials.

By providing a more accurate surrogate for human hepatitis-driven cancer, the model has the potential to improve the diagnosis and treatment options available to liver cancer patients.